Yano S - Search Results

1

The Brain Microenvironment Induces DNMT1 Suppression and Indolence of Metastatic Cancer Cells.

Hirata E, Ishibashi K, Kohsaka S, Shinjo K, Kojima S, Kondo Y, Mano H, Yano S, Kiyokawa E, Sahai E. Hirata E, et al. Among authors: yano s. iScience. 2020 Aug 20;23(9):101480. doi: 10.1016/j.isci.2020.101480. eCollection 2020 Sep 25. iScience. 2020. PMID: 32891059 Free PMC article.

2

Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.

Yamada T, Takeuchi S, Nakade J, Kita K, Nakagawa T, Nanjo S, Nakamura T, Matsumoto K, Soda M, Mano H, Uenaka T, Yano S. Yamada T, et al. Among authors: yano s. Clin Cancer Res. 2012 Jul 1;18(13):3592-602. doi: 10.1158/1078-0432.CCR-11-2972. Epub 2012 May 2. Clin Cancer Res. 2012. PMID: 22553343

3

Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice.

Wang R, Yamada T, Arai S, Fukuda K, Taniguchi H, Tanimoto A, Nishiyama A, Takeuchi S, Yamashita K, Ohtsubo K, Matsui J, Onoda N, Hirata E, Taira S, Yano S. Wang R, et al. Among authors: yano s. Mol Cancer Ther. 2019 May;18(5):947-956. doi: 10.1158/1535-7163.MCT-18-0695. Epub 2019 Mar 29. Mol Cancer Ther. 2019. PMID: 30926637

4

A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer.

Soh SX, Siddiqui FJ, Allen JC, Kim GW, Lee JC, Yatabe Y, Soda M, Mano H, Soo RA, Chin TM, Ebi H, Yano S, Matsuo K, Niu X, Lu S, Isobe K, Lee JH, Yang JC, Zhao M, Zhou C, Lee JK, Lee SH, Lee JY, Ahn MJ, Tan TJ, Tan DS, Tan EH, Ong ST, Lim WT. Soh SX, et al. Among authors: yano s. Oncotarget. 2017 Jun 20;8(25):41474-41486. doi: 10.18632/oncotarget.17102. Oncotarget. 2017. PMID: 28467813 Free PMC article. Review.

5

In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line.

Nanjo S, Nakagawa T, Takeuchi S, Kita K, Fukuda K, Nakada M, Uehara H, Nishihara H, Hara E, Uramoto H, Tanaka F, Yano S. Nanjo S, et al. Among authors: yano s. Cancer Sci. 2015 Mar;106(3):244-52. doi: 10.1111/cas.12600. Epub 2015 Feb 17. Cancer Sci. 2015. PMID: 25581823 Free PMC article.

6

mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF.

Ishikawa D, Takeuchi S, Nakagawa T, Sano T, Nakade J, Nanjo S, Yamada T, Ebi H, Zhao L, Yasumoto K, Nakamura T, Matsumoto K, Kagamu H, Yoshizawa H, Yano S. Ishikawa D, et al. Among authors: yano s. PLoS One. 2013 May 14;8(5):e62104. doi: 10.1371/journal.pone.0062104. Print 2013. PLoS One. 2013. PMID: 23690929 Free PMC article.

7

STAT3 inhibition suppresses adaptive survival of ALK-rearranged lung cancer cells through transcriptional modulation of apoptosis.

Yanagimura N, Takeuchi S, Fukuda K, Arai S, Tanimoto A, Nishiyama A, Ogo N, Takahashi H, Asai A, Watanabe S, Kikuchi T, Yano S. Yanagimura N, et al. Among authors: yano s. NPJ Precis Oncol. 2022 Feb 28;6(1):11. doi: 10.1038/s41698-022-00254-y. NPJ Precis Oncol. 2022. PMID: 35228642 Free PMC article.

8

Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.

Donev IS, Wang W, Yamada T, Li Q, Takeuchi S, Matsumoto K, Yamori T, Nishioka Y, Sone S, Yano S. Donev IS, et al. Among authors: yano s. Clin Cancer Res. 2011 Apr 15;17(8):2260-9. doi: 10.1158/1078-0432.CCR-10-1993. Epub 2011 Jan 10. Clin Cancer Res. 2011. PMID: 21220474

9

Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells.

Tanimoto A, Yamada T, Nanjo S, Takeuchi S, Ebi H, Kita K, Matsumoto K, Yano S. Tanimoto A, et al. Among authors: yano s. Oncotarget. 2014 Jul 15;5(13):4920-8. doi: 10.18632/oncotarget.2055. Oncotarget. 2014. PMID: 24952482 Free PMC article.

10

Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion-Positive Tumor Cells in a Brain Metastasis Model.

Nishiyama A, Yamada T, Kita K, Wang R, Arai S, Fukuda K, Tanimoto A, Takeuchi S, Tange S, Tajima A, Furuya N, Kinoshita T, Yano S. Nishiyama A, et al. Among authors: yano s. Clin Cancer Res. 2018 May 15;24(10):2357-2369. doi: 10.1158/1078-0432.CCR-17-1623. Epub 2018 Feb 20. Clin Cancer Res. 2018. PMID: 29463555

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,477 results

Search Page